Clinical Trials
Phase 3 Trial of Rova T as Second-line Therapy for Advanced Small-Cell Lung Cancer Halted
AbbVie , a research-based global biopharmaceutical company, announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer (SCLC). An...
Articles
The importance of biometric functions to improving data quality in Clinical Trials
Reducing the costs associated with clinical trials is one of the pharmaceutical industry’s core challenges. Running a clinical trial is incredibly expensive and if a compound fails in the late phases, it can be catastrophic for its sponsor company.
One...
Articles
How implementing electronic clinical outcome assessments (eCOA) into Oncology Clinical Trials Reduces the Burden of Data Collection
Clinical oncology research is unique when compared to other therapeutic areas. Cancer patients experience substantial physical and psychosocial consequences of the disease and its treatment and much of the symptom burden occurs outside the clinical environment.
Oncology research is uniquely...
Clinical Trials
AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV
AstraZeneca and MedImmune, its global biologics research and development arm, announced final overall survival (OS) results for the Phase III MYSTIC trial. A randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of...
Clinical Trials
Pharm-Olam is proud to have contributed to the execution and completion of Cablivi ivotal Phase III study
Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market...
Clinical Trials
REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314
REGENXBIO Inc. a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced updated results from the ongoing Phase I study of RGX-314 for the treatment...
Clinical Trials
Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.
Quotient Sciences, a leading drug development services organization, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. The $15 million...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.